Intestinal Research

Skip Navigation: Skip to contents

mobile search button mobile menu button

Search

Page Path: HOME > Search

Original Articles

IBD

Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study: Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye; Intest Res 2022;20(2):203-212. Published online April 29, 2022; DOI: https://doi.org/10.5217/ir.2021.00020

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Fecal S100A12 (FS) and serum S100A12 (SS) have been reported as novel biomarkers that accurately reflect intestinal inflammation. We evaluated if FS and SS in comparison to fecal calprotectin (FC) are associated with poor future outcomes in clinically quiescent Crohn’s disease (CD) patients.
Methods
We prospectively enrolled 49 CD patients in clinical remission (Crohn’s Disease Activity Index [CDAI] < 150 for the past 6 months). Patients were followed for a median period of 4.4 years (interquartile range [IQR], 4.3–4.5). The following outcomes were evaluated: clinical relapse, CD-related hospitalization, step-up of medical treatment, and CD-related intestinal resection. Cox proportional-hazard regression model was constructed to assess the association of baseline markers with time-to-event outcomes.
Results
The median levels of baseline FS, FC, and SS were 0.042 mg/kg (IQR, 0.005–0.179), 486.8 mg/kg (IQR, 203.5–886.8) and 1,398.2 ng/mL (IQR, 791.8–2,759.9), respectively. FS correlated with FC (r = 0.689), erythrocyte sedimentation rate (r = 0.524), C-reactive protein (r = 0.499), and albumin (r = –0.446), but not with CDAI (r = 0.045). Interestingly, increased FS (top quartile) was associated with a 4.9-fold increased rate of future CD-related hospitalization (P= 0.009) and a 2.8-fold increased rate of step-up of medical treatment (P= 0.032), whereas increased FC and SS were not. These findings remained significant after adjusting for age, sex, disease duration, current smoking, C-reactive protein, serum albumin, CDAI, and FC, individually.
Conclusions
In this pilot study, increased FS and not FC or SS, was significantly associated with increased rates of future CD-related hospitalization and step-up of medical treatment among CD patients in clinical remission.

Citations

Citations to this article as recorded by

Recent developments in biomarker guided therapy for Crohn’s disease
André Bargas, Joana Torres, Bram Verstockt
Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1241. CrossRef
Systematic analysis and characterization of long non-coding RNA genes in inflammatory bowel disease
Rania Velissari, Mirolyuba Ilieva, James Dao, Henry E Miller, Jens Hedelund Madsen, Jan Gorodkin, Masanori Aikawa, Hideshi Ishii, Shizuka Uchida
Briefings in Functional Genomics.2024; 23(4): 395. CrossRef
The role of fecal biomarkers in individuals with inflammatory bowel disease
Teagan S. Edwards, Andrew S. Day
Expert Review of Molecular Diagnostics.2024; 24(6): 497. CrossRef
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
Diogo Magalhaes, Laurent Peyrin-Biroulet, Maria Manuela Estevinho, Silvio Danese, Fernando Magro
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef

7,813 View
196 Download
3 Web of Science
4 Crossref

Inflammatory bowel diseases

Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey: Sun-Ho Lee, Kiju Chang, Ki Seok Seo, Yun Kyung Cho, Eun Mi Song, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park; Intest Res 2020;18(2):192-199. Published online April 3, 2020; DOI: https://doi.org/10.5217/ir.2019.00115

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The use of complementary and alternative medicine (CAM) is a global phenomenon, including inflammatory bowel disease (IBD) patients. We aimed to assess the change in prevalence and patterns of CAM use, and attitudes towards CAM over an 8-year time interval (2006 vs. 2014) among IBD patients in Korea.
Methods
A total of 221 IBD patients (CD=142, UC=79) were asked to complete a questionnaire regarding CAM at two time points: at enrollment (2006) and 8 years later (2014/2015).
Results
The proportion of patients ever using CAM increased significantly from 60.2% in 2006 to 79.6% in 2014 (P<0.001), while the proportion of current CAM users increased slightly (35.7% to 38.0%, P=0.635); 21.7% used CAM consistently at both time points. The proportion of patients who felt CAM was less effective (P<0.001) and more expensive (P=0.04) than conventional treatments increased over time. Also, the proportion among ever CAM users who perceived a positive effect from CAM significantly decreased in 2014 compared to 2006 (P=0.004). Higher education (adjusted odds ratio [aOR], 2.10), prior side effects to conventional therapies (aOR, 2.23), and prior use of corticosteroids (aOR, 2.51) were associated with CAM use. Interestingly, use of CAM before IBD diagnosis (aOR, 2.73) was significantly associated with consistent CAM use.
Conclusions
Although the attitudes toward CAM have become less favorable, the majority of IBD patients have experienced CAM with an overall increase of current CAM users over time. Moreover, more than half of current CAM users used CAM consistently over time.

Citations

Citations to this article as recorded by

Validation of the Korean Version of a Knowledge Assessment Tool for Children With Inflammatory Bowel Disease
Sowon Park, Jihye Noh, Chaelin Kim, Hyeji Lim, Eun Joo Lee, Hong Koh, Andrew S Day, Angharad Vernon-Roberts
Journal of Korean Medical Science.2026;[Epub] CrossRef
Effects of self-acupressure on quality of life and abdominal pain severity among patients with inflammatory bowel disease: A randomized sham-controlled trial
Nahid Rajai, Zahra Abbasi, Amir Hosein Pishgooie, Fatemeh Teymouri, Mohammad Imanipour
Journal of Ayurveda and Integrative Medicine.2025; 16(2): 101080. CrossRef
Use of Complementary and Alternative Medicine by Greek Patients with Inflammatory Bowel Disease
John Triantafillidis, Aristofanis Gikas, Georgia Kontrarou, Manousos Konstantoulakis, Apostolos Papalois
Nutrients.2024; 16(21): 3679. CrossRef
A comparative analysis of complementary therapies use among patients attending diabetic clinics in Taiwan: 2007 vs. 2023
Hsiao-Yun Chang, Yu-Yao Huang, Chin-Jung Chung, Feng-Hsuan Liu
BMC Complementary Medicine and Therapies.2023;[Epub] CrossRef
Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study
Eun Soo Kim, Chung Hyun Tae, Sung-Ae Jung, Dong Il Park, Jong Pil Im, Chang Soo Eun, Hyuk Yoon, Byung Ik Jang, Haruhiko Ogata, Kayoko Fukuhara, Fumihito Hirai, Kazuo Ohtsuka, Jing Liu, Qian Cao
Intestinal Research.2022; 20(2): 192. CrossRef
Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
Jae Song Kim, Min Jung Geum, Eun Sun Son, Yun Mi Yu, Jae Hee Cheon, Kyeng Hee Kwon
Gut and Liver.2022; 16(5): 736. CrossRef
Comprehensive study on the administrative, economic, regional, and regulatory prospects of complementary and alternative medicine (CAM) in inflammatory bowel disease (IBD)
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi
Expert Review of Clinical Pharmacology.2021; 14(7): 865. CrossRef
Complementary and alternative medicine in patients with inflammatory bowel disease: hype or evidence?
Jae Myung Cha
Intestinal Research.2020; 18(2): 141. CrossRef

8,515 View
126 Download
8 Web of Science
8 Crossref

First
Prev
Page of 1
Next
Last